Prostate-specific antigen (PSA) is a protein produced by cells in the prostate gland. Its normal job is to liquefy semen after ejaculation, but small amounts leak into the bloodstream, where they can be measured with a simple blood test. That blood level is used primarily as a screening and monitoring tool for prostate cancer, though many non-cancerous conditions raise PSA too.
What PSA Actually Does in the Body
PSA is a type of enzyme that breaks down proteins in seminal fluid. Specifically, it dissolves the gel-like consistency of semen so sperm can move freely. Production is driven by testosterone, which is why anything that affects prostate tissue or hormone levels can shift how much PSA ends up in your blood.
In a healthy prostate, only a tiny fraction of PSA escapes into the bloodstream. When prostate cells are damaged, inflamed, or multiplying abnormally, more PSA leaks out. That’s the principle behind using it as a marker: a rising blood level signals that something is happening in the prostate, even if that something isn’t necessarily cancer.
Normal PSA Levels by Age
There is no single “normal” number. PSA naturally rises as the prostate grows with age, so reference ranges shift by decade:
- Ages 40 to 50: 0 to 2.5 ng/mL
- Ages 50 to 60: 2.5 to 3.5 ng/mL
- Ages 60 to 70: 3.5 to 4.5 ng/mL
- Ages 70 to 80: 4.5 to 5.5 ng/mL
Values above these thresholds are considered abnormal for your age group, but “abnormal” does not automatically mean cancer. It means further evaluation is warranted.
Why PSA Rises Without Cancer
An elevated PSA catches many people off guard, and in a large number of cases the cause turns out to be benign. Common non-cancerous reasons include:
- Benign prostatic hyperplasia (BPH): An enlarged prostate simply has more cells producing PSA.
- Prostatitis: Infection or inflammation of the prostate can spike PSA dramatically. In one study of 72 patients, 71% of those with acute prostatitis had levels above 4 ng/mL, compared to 15% with chronic bacterial prostatitis and just 6% with non-bacterial prostatitis.
- Urinary tract infections: Infection in the urinary system can irritate prostate tissue enough to push PSA higher.
- Prostate cysts or abscesses: Rare structural issues have been reported to elevate PSA well above typical ranges.
Even extremely high readings don’t guarantee malignancy. Case reports have documented PSA levels above 1,000 ng/mL from acute prostatitis alone, though non-cancerous causes generally produce levels under 50 ng/mL.
What Can Temporarily Skew Your Results
Several everyday activities and medical events can inflate your PSA reading for a short time. Vigorous exercise, particularly cycling, and recent ejaculation both cause transient increases. The National Cancer Institute recommends avoiding these activities for at least two days before testing. A recent prostate biopsy or an active prostate infection can keep levels elevated for a month or two, so testing is typically postponed until those issues resolve.
Medications matter too. Finasteride and dutasteride, commonly prescribed for an enlarged prostate or hair loss, reduce PSA by roughly 50% after six months of use. If you take either of these, your measured PSA should be doubled before comparing it to standard reference values. After several years on these drugs, the adjustment factor increases to about 2.5 times the measured level. Without that correction, a genuinely concerning PSA could look deceptively normal.
Free PSA and PSA Density
When a standard PSA result falls in a gray zone, typically between 4 and 10 ng/mL, additional calculations can help clarify the picture.
PSA circulates in two forms: bound to other proteins or floating freely. The percentage of free PSA relative to total PSA offers a clue about cancer risk. In one study of men with PSA levels at or below 10 ng/mL, a free PSA ratio below 17.6% was associated with clinically significant cancer in 34% of cases, while only 4% of men with a ratio above 17.6% had significant cancer. A lower free PSA percentage raises suspicion; a higher one is more reassuring and may help you avoid an unnecessary biopsy.
PSA density takes a different approach: it divides your total PSA by the volume of your prostate, measured on ultrasound or MRI. A larger prostate naturally produces more PSA, so adjusting for size helps distinguish a big, benign gland from a smaller one harboring cancer. Cutoff values vary by institution, but a density around 0.13 ng/mL per cubic centimeter has shown sensitivity and specificity above 90% in some settings.
What Happens After an Elevated Result
There is no single PSA number that automatically triggers a biopsy. The process is stepwise. Your first elevated reading will typically be followed by a repeat PSA test, sometimes several weeks later, to confirm the result wasn’t a temporary spike. If the elevation persists, a digital rectal exam gives a physical assessment of the prostate’s size and texture.
The next step is usually imaging, most often an MRI of the prostate, which can highlight suspicious areas that might warrant closer inspection. A prostate biopsy, where small tissue samples are collected and examined under a microscope, remains the only definitive way to diagnose prostate cancer. But the decision to biopsy is made by weighing the full picture: your PSA trend over time, free PSA ratio, imaging findings, age, family history, and personal preferences.
Current Screening Recommendations
The U.S. Preventive Services Task Force treats PSA screening as a personal decision rather than a universal recommendation. For men aged 55 to 69, the task force assigns a Grade C recommendation, meaning the potential benefit of catching cancer early is real but small, and it should be weighed against the possibility of false positives, unnecessary biopsies, and overtreatment of slow-growing cancers that may never cause symptoms. For men 70 and older, the task force recommends against routine screening entirely (Grade D).
Family history, race, and overall health all factor into whether screening makes sense for you individually. Black men and those with a first-degree relative diagnosed with prostate cancer face higher risk and may benefit from earlier conversations about testing, sometimes starting in their 40s. The key point is that screening is not a one-size-fits-all decision, and an informed choice requires understanding both what PSA can and cannot tell you.